Nilotinib: all 136 studies that test it

Page 1 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingNCT06409936Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingNCT04903119Phase 1
• Asciminib Roll-over StudyRecruitingNCT04877522Phase 4
• Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingNCT04838041Phase 2
• Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelRecruitingNCT04449549Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
• Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedNCT05185947Phase 2Results posted
• Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast CancerCompletedNCT04205903Phase 1Results posted
• Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy BodiesCompletedNCT04002674Phase 2Results posted
• Nilotinib in Parkinson's DiseaseCompletedNCT03205488Phase 2Results posted
• Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid LeukemiaTerminatedNCT02709083Phase 2Results posted
• Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.CompletedNCT02546674Phase 4Results posted
• Stem Cell Monitoring for CML Patients Undergoing Nilotinib TherapyCompletedNCT02353728Phase 2Results posted
• A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted
• The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)CompletedNCT02269267Phase 2Results posted
• Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to NilotinibTerminatedNCT02115386Phase 3Results posted
• Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.TerminatedNCT02108951Phase 3Results posted
• Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib TreatmentCompletedNCT01863745Phase 2Results posted
• Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.CompletedNCT01844765Phase 2Results posted
• Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01806571Phase 2Results posted
• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) PatientsCompletedNCT01784068Phase 2Results posted
• A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment CessationCompletedNCT01744665Phase 2Results posted
• A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.CompletedNCT01743989Phase 3Results posted
• Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored StudyCompletedNCT01735955Phase 4Results posted
• Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)CompletedNCT01698905Phase 2Results posted
• Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.CompletedNCT01289028Phase 3Results posted
• Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01275586Early Phase 1Results posted
• Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP PatientsCompletedNCT01275196Phase 3Results posted
• Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT01274351Phase 2Results posted
• Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia PatientsCompletedNCT01254188Phase 3Results posted
• CMR Rate of Newly Diagnosed CML-CP Patients Treated With NilotinibCompletedNCT01227577Phase 4Results posted
• Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell TumorCompletedNCT01207492Phase 2Results posted
• Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)TerminatedNCT01179737Phase 2Results posted
• Nilotinib in the Treatment of Systemic SclerosisCompletedNCT01166139Phase 2Results posted
• Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant GliomasCompletedNCT01140568Phase 2Results posted
• Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma ConcentrationsTerminatedNCT01131325Phase 4Results posted
• Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)TerminatedNCT01089595Phase 2Results posted
• A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)CompletedNCT01077544Phase 1Results posted
• Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01061177Phase 4Results posted
• Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponseCompletedNCT01043874Phase 4Results posted
• A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit MutationCompletedNCT01028222Phase 2Results posted
• An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib TreatmentCompletedNCT00980018Phase 4Results posted
• Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to ImatinibCompletedNCT00802841Phase 3Results posted
• Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaCompletedNCT00788775Phase 2Results posted
• A Study of Nilotinib Versus Imatinib in GIST PatientsCompletedNCT00785785Phase 3Results posted
• Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)TerminatedNCT00782834Phase 2Results posted
• Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)CompletedNCT00760877Phase 3Results posted
• Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibCompletedNCT00756509Phase 4Results posted
• Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 MgTerminatedNCT00751036Phase 3Results posted
• Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CMLCompletedNCT00702403Phase 1/2Results posted
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to ImatinibTerminatedNCT00644878Phase 2Results posted
• Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)TerminatedNCT00519090Phase 3Results posted
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT00471497Phase 3Results posted
• Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00129740Phase 2Results posted
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
• Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibCompletedNCT00036738Phase 2Results posted
• A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.CompletedNCT07138378Phase 1
• A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
• A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of MeforminCompletedNCT04448821Phase 1
• Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaActive, not recruitingNCT04147533Phase 2
• Nilotinib for First-line Newly Diagnosed CML-CP PatientsStatus unknownNCT03942094Phase 3
• Effect of Nilotinib in Cerebellar Ataxia PatientsCompletedNCT03932669Phase 2
• Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
• Nilotinib in Huntington's DiseaseStatus unknownNCT03764215Phase 1
• Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
• Efficacy and Safety of Nilotinib in CML-CPCompletedNCT03332511Phase 4
• Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT03228303Early Phase 1
• A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
• 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patientsActive, not recruitingNCT02917720Phase 2
• Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the HostCompletedNCT02891395Phase 2
• Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon CancerWithdrawnNCT02774512Early Phase 1
• Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to DasatinibStatus unknownNCT02389920Phase 4
• Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCompletedNCT02379416Phase 1
• Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular ResponseCompletedNCT02326311Phase 3
• Nilotinib in Cognitively Impaired Parkinson Disease Patients 001CompletedNCT02281474Phase 1
• Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsCompletedNCT02253277Phase 1
• An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
• Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib TherapyTerminatedNCT02086487Phase 4
• Pharmacokinetic Comparison of XS003 and TasignaCompletedNCT02068898Phase 1
• Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaCompletedNCT02001818Phase 2
• Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
• Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young AdultsTerminatedNCT01887522Phase 2
• Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young AdultsCompletedNCT01884922Phase 1
• A Phase I Study of Nilontinib and Cetuximab in Patients With Solid TumorsTerminatedNCT01871311Phase 1
• Nilotinib Plus Pegylated Interferon-α2b in CMLTerminatedNCT01866553Phase 2
• Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ CellsCompletedNCT01856283Phase 2
• Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment IntoleranceCompletedNCT01819389Phase 3
• Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHDCompletedNCT01810718Phase 1
• De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid LeukaemiaCompletedNCT01804985Phase 2
• Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)CompletedNCT01774630Phase 2
• Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
• Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AMLStatus unknownNCT01690065Phase 2
• Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous LeukemiaWithdrawnNCT01670084Phase 2
• Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.WithdrawnNCT01605981Phase 4
• Nilotinib in PH+, BCR-, ABL+ CML PatientsCompletedNCT01535391Phase 3
• Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT01528085Phase 2
• Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior TherapyCompletedNCT01456676Phase 1
• Nilotinib With Radiation for High Risk ChordomaCompletedNCT01407198Phase 1

← Nilotinib overview